Beta Bionics (BBNX) CMO sells 4,222 shares to cover tax obligations

Rhea-AI Filing Summary

Beta Bionics, Inc. Chief Medical Officer Russell Steven Jon reported an open-market sale of 4,222 shares of common stock on June 2, 2026. The shares were sold to cover tax withholding obligations arising from the vesting of restricted stock units.

The weighted average sale price was $12.6071 per share, with individual trade prices ranging from $12.30 to $12.93. After these transactions, he directly holds 173,849 shares of Beta Bionics common stock, indicating this was a relatively small, tax-driven sale.

Insider Trade Summary

Net Seller: 4,222 shares ($53,227)

Net Sell 1 txn

Insider Russell Steven Jon

Role Chief Medical Officer

Sold 4,222 shs ($53K)

Type	Security	Shares	Price	Value
Sale	Common Stock	4,222	$12.6071	$53K

Holdings After Transaction: Common Stock — 173,849 shares (Direct, null)

Footnotes (1)

1. The shares were sold to cover tax withholding obligations associated with the vesting of restricted stock units. The weighted average sale price for the transaction reported was $12.6071 and the range of prices were between $12.30 and $12.93. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

Key Figures

Shares sold: 4,222 shares Weighted average sale price: $12.6071 per share Sale price range: $12.30–$12.93 per share +2 more

5 metrics

Shares sold 4,222 shares Open-market sale on June 2, 2026

Weighted average sale price $12.6071 per share Common stock sale to cover tax withholding

Sale price range $12.30–$12.93 per share Range of prices for reported transaction

Shares held after transaction 173,849 shares Directly held by CMO following sale

Net shares sold 4,222 shares Net-sell direction in this Form 4

Key Terms

restricted stock units, weighted average sale price, open-market sale, tax withholding obligations

4 terms

restricted stock units financial

"cover tax withholding obligations associated with the vesting of restricted stock units"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

weighted average sale price financial

"The weighted average sale price for the transaction reported was $12.6071"

open-market sale financial

"transaction_action": "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

tax withholding obligations financial

"sold to cover tax withholding obligations associated with the vesting"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Russell Steven Jon

(Last) (First) (Middle)

C/O BETA BIONICS, INC.

11 HUGHES

(Street)

IRVINE CALIFORNIA 92618

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Beta Bionics, Inc. [ BBNX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/02/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/02/2026		S(1)		4,222	D	$12.6071(2)	173,849	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The shares were sold to cover tax withholding obligations associated with the vesting of restricted stock units.

2. The weighted average sale price for the transaction reported was $12.6071 and the range of prices were between $12.30 and $12.93. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

	/s/ Stephen Feider, Attorney-in-Fact	06/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Beta Bionics (BBNX) report in this Form 4?

Beta Bionics reported that its Chief Medical Officer, Russell Steven Jon, sold 4,222 shares of common stock. The sale occurred on June 2, 2026, and was linked to tax withholding obligations from vesting restricted stock units rather than a discretionary portfolio move.

Why did the Beta Bionics CMO sell 4,222 BBNX shares?

The 4,222 shares were sold specifically to cover tax withholding obligations tied to the vesting of restricted stock units. This indicates the transaction was primarily a tax-related event instead of a strategic decision to significantly reduce exposure to Beta Bionics stock.

What was the sale price range for the BBNX shares sold by the CMO?

The weighted average sale price was $12.6071 per share, with individual sales executed between $12.30 and $12.93. This range reflects normal market trading around that average, with full price breakdowns available upon request from the company or regulators.

How many Beta Bionics shares does the CMO hold after this Form 4 transaction?

After the sale, the Chief Medical Officer directly holds 173,849 shares of Beta Bionics common stock. Compared with the 4,222 shares sold, this indicates he retains the vast majority of his reported holdings following the tax-related transaction disclosed here.

Was the Beta Bionics CMO’s sale a routine tax transaction or a large discretionary sale?

The filing notes the shares were sold to meet tax withholding needs from restricted stock unit vesting, indicating a routine tax-related transaction. The 4,222 shares represent a small portion relative to his remaining 173,849 directly held shares.